Pfizer (PFE) Competitors $26.30 -0.19 (-0.71%) As of 01/17/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PFE vs. JNJ, ABBV, MRK, BMY, ZTS, RPRX, JAZZ, CORT, PRGO, and SUPNShould you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry. Pfizer vs. Johnson & Johnson AbbVie Merck & Co., Inc. Bristol-Myers Squibb Zoetis Royalty Pharma Jazz Pharmaceuticals Corcept Therapeutics Perrigo Supernus Pharmaceuticals Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability. Which has higher valuation and earnings, PFE or JNJ? Johnson & Johnson has higher revenue and earnings than Pfizer. Johnson & Johnson is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPfizer$58.50B2.55$2.12B$0.7435.55Johnson & Johnson$85.16B4.16$35.15B$6.9121.28 Is PFE or JNJ a better dividend stock? Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 6.4%. Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.4%. Pfizer pays out 227.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson pays out 71.8% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years and Johnson & Johnson has increased its dividend for 63 consecutive years. Is PFE or JNJ more profitable? Johnson & Johnson has a net margin of 19.14% compared to Pfizer's net margin of 7.07%. Johnson & Johnson's return on equity of 35.45% beat Pfizer's return on equity.Company Net Margins Return on Equity Return on Assets Pfizer7.07% 16.28% 6.68% Johnson & Johnson 19.14%35.45%14.23% Do insiders & institutionals believe in PFE or JNJ? 68.4% of Pfizer shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts rate PFE or JNJ? Pfizer currently has a consensus price target of $32.00, suggesting a potential upside of 21.66%. Johnson & Johnson has a consensus price target of $174.29, suggesting a potential upside of 18.54%. Given Pfizer's stronger consensus rating and higher possible upside, research analysts plainly believe Pfizer is more favorable than Johnson & Johnson.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pfizer 1 Sell rating(s) 8 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.50Johnson & Johnson 0 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.46 Which has more risk and volatility, PFE or JNJ? Pfizer has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Does the media refer more to PFE or JNJ? In the previous week, Johnson & Johnson had 26 more articles in the media than Pfizer. MarketBeat recorded 106 mentions for Johnson & Johnson and 80 mentions for Pfizer. Pfizer's average media sentiment score of 1.12 beat Johnson & Johnson's score of 1.00 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 57 Very Positive mention(s) 11 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Johnson & Johnson 79 Very Positive mention(s) 9 Positive mention(s) 12 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Does the MarketBeat Community favor PFE or JNJ? Pfizer received 391 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 69.00% of users gave Pfizer an outperform vote while only 65.15% of users gave Johnson & Johnson an outperform vote. CompanyUnderperformOutperformPfizerOutperform Votes150769.00% Underperform Votes67731.00% Johnson & JohnsonOutperform Votes111665.15% Underperform Votes59734.85% SummaryJohnson & Johnson beats Pfizer on 13 of the 22 factors compared between the two stocks. Get Pfizer News Delivered to You Automatically Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PFE vs. The Competition Export to ExcelMetricPfizerPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$149.06B$6.22B$5.21B$19.94BDividend Yield6.29%2.94%5.13%3.71%P/E Ratio35.559.8789.3441.41Price / Sales2.55309.211,240.0416.25Price / Cash8.9861.4443.7519.84Price / Book1.666.055.315.76Net Income$2.12B$154.90M$122.54M$993.25M7 Day Performance-1.82%-0.32%0.59%3.12%1 Month Performance-0.22%0.43%2.55%4.75%1 Year Performance-6.99%3.08%25.29%18.83% Pfizer Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PFEPfizer4.9917 of 5 stars$26.30-0.7%$32.00+21.7%-7.0%$149.06B$58.50B35.5588,000Positive NewsJNJJohnson & Johnson4.9423 of 5 stars$147.03-0.5%$174.29+18.5%-9.0%$353.99B$85.16B21.28131,900Upcoming EarningsAnalyst DowngradeNews CoverageABBVAbbVie4.9944 of 5 stars$171.49-1.3%$205.50+19.8%+4.1%$303.05B$54.32B59.5550,000Short Interest ↓Analyst RevisionPositive NewsMRKMerck & Co., Inc.4.9993 of 5 stars$98.00-2.7%$123.67+26.2%-17.6%$247.91B$60.12B20.5572,000News CoveragePositive NewsBMYBristol-Myers Squibb4.9068 of 5 stars$56.350.0%$56.27-0.2%+12.5%$114.30B$45.01B-15.7034,100Short Interest ↓Positive NewsZTSZoetis4.8255 of 5 stars$166.01-2.0%$211.89+27.6%-11.9%$74.90B$8.54B31.2014,100Analyst RevisionNews CoveragePositive NewsHigh Trading VolumeRPRXRoyalty Pharma4.7372 of 5 stars$30.75-0.6%$41.67+35.5%+5.8%$18.12B$2.36B15.9380Positive NewsJAZZJazz Pharmaceuticals4.9819 of 5 stars$121.18-1.2%$177.00+46.1%+4.0%$7.33B$3.83B17.072,800Short Interest ↓CORTCorcept Therapeutics4.541 of 5 stars$55.31+1.6%$65.25+18.0%+126.5%$5.80B$482.38M43.90300Positive NewsPRGOPerrigo4.9513 of 5 stars$23.86+0.0%$35.00+46.7%-27.9%$3.26B$4.66B-20.409,140SUPNSupernus Pharmaceuticals3.7359 of 5 stars$37.74-0.3%$46.50+23.2%+36.4%$2.08B$651.97M35.27580Positive News Related Companies and Tools Related Companies Johnson & Johnson Alternatives AbbVie Alternatives Merck & Co., Inc. Alternatives Bristol-Myers Squibb Alternatives Zoetis Alternatives Royalty Pharma Alternatives Jazz Pharmaceuticals Alternatives Corcept Therapeutics Alternatives Perrigo Alternatives Supernus Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:PFE) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pfizer Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pfizer With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PFE Stock Alerts